CRTC3 and schizophrenia: Given that AREG treatment modulates the frontoparietal pathway and noting that CRTC3 and amphiregulin are associated with mental disorders affecting how the brain perceives the world, such as schizophrenia [13, 38, 39], autism [40], as well as mood depressive disorder [12], our findings suggest a new approach to treating such psychiatric disorders either as disease-modifying (restoring perturbed brain function) or symptom-alleviating (alleviating anti-social or dissocial symptoms) treatments.